Corryn Biotechnologies Secures £150K for Innovative Wound Care
Corryn Biotechnologies Ltd, an innovative medtech startup based in South Wales, has successfully garnered a substantial investment amounting to £150,000 from the British Design Fund. This investment is a crucial component of a larger £550,000 seed funding round aimed at propelling the advancement of the company’s groundbreaking wound dressing technology. Designed specifically for the treatment of chronic and complex wounds, this novel solution represents a significant leap forward in the field of wound care management. By leveraging advanced techniques in regenerative medicine, Corryn Biotechnologies is working diligently to elevate the standards of patient care and expedite the healing process.
At the helm of this pioneering initiative is Luke Burke, co-founder and CEO of Corryn Biotechnologies.
Luke articulates a pressing concern: “Around the world, wounds are still being treated largely the same way as they were 150 years ago, with dressings that are often not fit for purpose, leading to a slow, painful treatment process and poor outcomes for patients.” This insight serves as a catalyst for change, inspiring Corryn Biotechnologies to develop a unique handheld wound care device. Utilizing a patent-pending method, this device creates advanced wound dressings composed of microscopic polymer fibers. These fibers mimic the natural cellular structure found in the body, allowing for a breathable and flexible protective layer that is applied painlessly at the point of care, gradually breaking down and being absorbed by the body over time.
As the company looks ahead, they are enthusiastic about their growth trajectory and future clinical trials. Luke expressed gratitude for the support received from the British Design Fund and their other investors, emphasizing their shared vision of improving healthcare outcomes: “We’re delighted to have secured the backing of British Design Fund... We’re currently finalising our clinical materials and have developed a research and manufacturing centre in Port Talbot, South Wales, that will enable us to meet demand until at least 2030 for our US and European markets.” Meanwhile, Damon Bonser, CEO at the British Design Fund, praised the efforts of Corryn Biotechnologies, noting their potential to revolutionize clinical care in chronic wound treatment. This collaboration signifies a promising future for both companies, with the potential to impact patient lives on a global scale.
They've invested in Corryn Biotechnologies
Get to know these Healthtech investors
Click here for a full list of 6,312+ startup investors in the UK